Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...

has now been approved for clinical trials in both Hong Kong and New Zealand DURHAM, N.C. & SEATTLE, January 07, 2025--(BUSINESS WIRE)--Leading epigenetic therapy company Tune Therapeutics ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

has now been approved for clinical trials in both Hong Kong and New Zealand DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenetic therapy company Tune Therapeutics announced today that it will ...

The first patients for the Phase 3 studies will be dosed in mid-2025. Durham’s Tavros Therapeutics sold to subsidiary of German giant Bayer AG Durham-based Tavros Therapeutics, a precision oncology ...